GSTA12P: Potential Drug Target and Biomarker for Xenobiotics and Neurodegenerative Disorders

Target Name: GSTA12P

NCBI ID: G647169

GSTA12P

Other Name(s): Glutathione S-transferase alpha 3 pseudogene | glutathione S-transferase alpha 12, pseudogene | LOC647169 | GSTAP5

GSTA12P: Potential Drug Target and Biomarker for Xenobiotics and Neurodegenerative Disorders

Glutathione S-transferase alpha 3 (GSTA12P) is a gene that encodes a protein known as GSTA12P, which is a key enzyme in the detoxification process of xenobiotics, such as drugs, toxins, and other harmful substances that can cause harm to the body. The GSTA12P gene has been identified as a potential drug target and a biomarker for various diseases, including drug addiction, neurodegenerative disorders, and autoimmune diseases.

The GSTA12P gene is located on chromosome 6p21.3 and encodes a protein that belongs to the family of transmembrane proteins, which are involved in the regulation of various physiological processes in the body, including cell signaling, inflammation, and signaling pathways. GSTA12P is a single-chain protein that contains 119 amino acid residues and has a calculated molecular weight of 12.5 kDa.

GSTA12P is involved in the detoxification process of xenobiotics, which are substances that can cause harm to the body. Xenobiotics are often found in our diet, such as bacteria, viruses, and other microorganisms that can cause illness. Many of these substances are also drugs that can harm the body, such as antibiotics, chemotherapy drugs, and other medications. The detoxification process is important for removing these harmful substances from the body, and GSTA12P is a key enzyme in this process.

GSTA12P is also involved in the regulation of cell signaling pathways. It has been shown to be involved in the signaling pathway that regulates cell growth, differentiation, and survival. This pathway is known as the TGF-β pathway, and it is involved in the development and maintenance of tissues and organs. GSTA12P has also been shown to be involved in the regulation of the Wnt signaling pathway, which is involved in the development and maintenance of tissues and organs during embryonic development.

In addition to its role in the detoxification process and cell signaling pathways, GSTA12P has also been shown to be involved in the regulation of neurodegenerative disorders. Many neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles. GSTA12P has been shown to be involved in the regulation of the production of these tangles, as well as the clearance of neurofibrillary tangles that can cause the progressive loss of brain cells.

Furthermore, GSTA12P has also been shown to be involved in the regulation of autoimmune diseases. Many autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis, are characterized by the immune system attacking the body's own tissues and organs. GSTA12P has been shown to be involved in the regulation of the production of autoantibodies, which are antibodies produced by the immune system that can cause inflammation and damage to the body's tissues.

In conclusion, GSTA12P is a gene that encodes a protein involved in the detoxification process of xenobiotics and the regulation of cell signaling pathways. It has also been shown to be involved in the regulation of neurodegenerative disorders and autoimmune diseases. As a result, GSTA12P is a potential drug target and a biomarker for these diseases, and it may be a valuable tool for the development of new treatments for these conditions.

Protein Name: Glutathione S-transferase Alpha 12, Pseudogene

The "GSTA12P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GSTA12P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets